SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance

Therapeutic responses to identical chemotherapy regimens often vary significantly among patients with the same type of cancer, underscoring the need for additional biomarkers to identify individuals most likely to benefit from specific treatments. The expression of SLFN11 (Schlafen11) has been ident...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Kunzhong Zhou, Yuewen Li, Weifang Wang, Yilin Chen, Bingyan Qian, Yiteng Liang, Hongmei Li, Ruiting Xu, Li Zhuang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-07-01
Subjects:	Schlafen11 (SLFN11) DNA damaging agents PARP inhibitors pan-cancer DNA damage repair mechanisms epigenetics
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1582738/full